Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participants
Year: 2024
Type: preprint
Abstract: INTRODUCTION Delaying cognitive decline in Alzheimer’s disease can significantly impact both function and quality of life. METHODS Longitudinal analysis of National Alzheimer’s Coordinating Center (NACC) dataset of 7,653 mild dementia CDR-SB AD participants at baseline with prescriptions for diabetes (DBMD), lipid-lowering (LIPL), anti-hypertensive (AHTN), and non-steroidal anti-inflammatory (NSD) medications over 10 years was evaluated for change in cognitive function relative to non-treated stratified by sex and APOE genotype. RESULTS Combination therapy of DBMD+LIPL+AHTN+NSD resulted in a 44% / 35% (MMSE/CDR-SB) delay in cognitive decline at 5 years and 47% / 35% (MMSE/CDR-SB) delay at 10 years. Females and APOE4 carriers exhibited greatest cognitive benefit of combination therapy. DISCUSSION Combination therapies significantly delayed cognitive decline in NACC AD participants at a magnitude comparable to or greater than beta-amyloid immunomodulator interventions. These data support combination precision medicine targeting AD risk factors to alter the course of the disease that persists for a decade.
Source: medRxiv
Authors: Yuan Shang, Georgina Torrandell-Haro, Francesca Vitali, Roberta Diaz Brinton
Institution: University of Arizona
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4391445800